Respiratory syncytial virus (RSV), the major cause of lower respiratory tract disease in infants, is thought to infect the upper airways before spreading to the lower respiratory tract. A rhesus monkey model of RSV infection after upper airway inoculation was used to test the protective effect of intranasal treatment with HNK20, a mouse monoclonal IgA antibody against RSV F glycoprotein. HNK20 was administered once daily for 2 days before RSV challenge and 4 days after challenge. Treatment with 0.5 mglkg HNK20 reduced viral shedding in the nose, throat, and lungs by [3] [4] loguJmL (P~.002). All monkeys developed RSV neutralizing antibody in serum, even in the absence of detectable viral replication. Neutralizing concentrations of monoclonal antibody remained in nasal secretions for > 1 day after treatment. These results suggest that nose-drop application of monoclonal antibody could provide convenient and effective protection against RSV infection in human infants at risk of severe lower respiratory tract disease.
Efforts to develop a vaccine against respiratory syncytial virus (RSV), the major cause of lower respiratory tract disease in infants and young children, have been hampered by the short duration of immunity to the virus, interference by maternal antibody, and vaccine-induced immunopotentiation of disease [1] [2] [3] . Passive immunization has shown promise as an alternative to vaccination for prevention ofRSV infection and disease. In a variety of animal models, parenteral treatment with monoclonal or polyclonal antibodies to RSV limits infection and disease of the lower respiratory tract [3 -6] . Intranasal administration of antibodies is also highly effective [7] [8] [9] [10] [11] and has the advantage of providing better protection of the upper respiratory tract [12] . Monoclonal antibodies against RSV show particular promise because of their high potency and because key neutralizing epitopes of the fusion (F) glycoprotein are conserved among strains of the two virus subgroups that infect humans [13] .
In humans, RSV infection starts in the upper airways and, in some cases, spreads to the lower respiratory tract [2] . Severe lower respiratory tract disease can occur in children with underlying conditions of the heart or lungs [2, 14] . In animal studies of RSV infection, virus is typically delivered directly into the lungs, often by allowing anesthetized animals to aspirate liquid administered into the nostrils. Topical antibody treatments are usually delivered into the lungs in the same manner.
To better mimic human infection, we developed a rhesus monkey model of RSV infection in which the virus inoculum was directed to the upper airways only, and subsequent viral shedding was assessed in both upper and lower respiratory tract secretions. Using this model, we examined the effect of once daily intranasal treatment with HNK20, a mouse monoclonal IgA antibody against RSV F glycoprotein that was shown previously to reduce upper and lower respiratory tract infection in mice [12] . Antibody treatment was also directed to the upper airways, allowing us to model daily nose-drop treatment of humans with natural challenge during the treatment period. Viral shedding was assessed in throat and nasal swab specimens and in bronchoalveolar lavage (BAL) fluids for 14 days after viral challenge. Respiratory tract specimens were also tested for mouse IgA concentration to determine the residence time of HNK20 on the mucosal surface. Postchallenge serum samples were tested for RSV neutralizing activity to determine the effect of treatment on development of antiviral immunity.
Materials and Methods
Virus. The Long strain ofRSV was used (ATCC VR26; American Type Culture Collection, Rockville, MD). The virus was passed once in rhesus monkeys and an isolate obtained from a terminal dilution of a throat swab specimen. The virus was confirmed as RSV by typical cytopathic changes induced in HEp-2 cells, by neutralization with reference RSV antiserum (NIH, Research Reagents Branch), and by immunofluorescent staining with fluorescein-labeled goat antiserum to RSV (Biodesign International, Kennebunkport, ME). Virus stock was prepared in HEp-2 cells and stored at -70°C.
Antibody production. Hybridoma cells producing mouse monoclonal IgA antibody HNK20 against RSV F glycoprotein [12] were grown in protein-free culture medium (serum-free and protein-free hybridoma medium; Sigma, St. Louis) using a hollowfiber bioreactor (AcuSyst Maximizer 1000; Cellex, Minneapolis). Antibody was purified using a procedure described previously [15J with some modifications. In brief, a low-pH viral inactivation step was followed by Q-Sepharose and DEAE-Sepharose anion-exchange chromatography steps and Sephacryl S-300 size-exclusion chromatography (Soman G, unpublished procedure). The resulting material was >90% pure and was composed primarily of dimeric and polymeric IgA with < 10% monomers. Protein concentration was determined by Lowry protein assay.
Animals and RSV challenge model. Young adult rhesus monkeys (Macaca mulatta) weighing 2.7-6.0 kg were selected for study. Monkeys were free of serum neutralizing antibody to RSV and had not been used in previous RSV challenge or vaccination experiments. Monkeys were lightly anesthetized with ketamine, allowing intranasal administration of antibody while maintaining the gag reflex. Antibody or PBS placebo was administered in drops (0.25 mL/nostril), the head rocked back and forth, and the monkey placed in the supine position for 15 min before being returned to its cage. Virus (10 5 .
7 TCID 50 RSV) was inoculated in the same manner, using the same volume of material.
Throat and nasal swabs were collected daily, prior to administration of antibody. Swabs were placed in 1 mL of culture medium (MEM supplemented with 5% fetal bovine serum and antibiotics), stored on ice, and assayed for infectivity within 1 h. BAL was done on days 4, 7, 10, and 14 by infusing 15 mL of sterile saline into one lobe of the lung and aspirating~5-7 mL of fluid. Swab and lavage specimens were assayed for infectivity in half-log., dilution steps in HEp-2 cells. Titers are expressed as the greatest dilution giving viral cytopathology per milliliter. For calculation of means, samples in which no virus was detected «1 10glO/mL) were assigned a titer of 0.5 10glO/mL.
Statistical analysis was done using JMP 3.0.2 software (SAS Institute, Cary, NC), with P~.05 considered significant.
Neutralization assays and ELISA. Serum neutralizing antibody titers were determined by preparation of 2-fold dilutions of heatinactivated (56°C, 30 min) sera in MEM with 5% fetal bovine serum. The dilutions were mixed with an equal volume of RSV containing 100 infectious doses of virus. The serum-virus mixtures were incubated at room temperature for 1 h, and each mixture was inoculated into duplicate wells of 24-well plates seeded with HEp-2 cells. The plates were read microscopically after 5-7 days of incubation at 37°C in a 5% CO 2 incubator and the viral cytopathology recorded. Reciprocal titers are expressed as the highest dilution of serum at which no viral cytopathology was observed.
The concentration of mouse IgA in respiratory tract specimens was determined by an antigen-capture ELISA. Microtiter plates were coated with goat anti-mouse IgA antibody (Southern Biotechnology Associates, Birmingham, AL) at I Ilg/mL in carbonatebicarbonate buffer, pH 9.6. Samples were diluted 1:5 or greater in blocking buffer (PBS containing 0.05% Tween 20 and 2.5% nonfat dry milk). A standard curve, constructed with purified HNK20, was included on each plate. Samples and standards were tested in duplicate, and plates incubated for 2 h at 28°C. Wells were incubated with biotin-conjugated goat anti-mouse IgA (Southern Biotechnology) for I h at 28°C, followed by streptavidin-alkaline phosphatase conjugate (Calbiochem, San Diego) for 1 h at 28°C. Plates were developed with p-nitrophenyl phosphate (Sigma) and absorbance read at 405 nm with a Vmax plate reader (Molecular Devices, Menlo Park, CA). Softmax software (Molecular Devices) was used to perform a four-parameter curve fit and to calculate HNK20 concentrations in samples. The assay was accurate to~0.4 ng/mL, allowing quantitation of HNK20 to as low as 2 ng/ml. at a minimum sample dilution of I :5. Samples with <2 ng/ml, HNK20 but with ELISA A 40 5 >0.100 were considered postive but could not be quantified.
To measure the concentration of HNK20 capable of binding to antigen, the assay for mouse IgA was modified so that test plates were coated with RSV -infected cell lysate antigen in place of antimouse IgA. To prepare lysate antigen, RSV-infected Vero cell monolayers were treated with detergent lysis buffer (1% Triton X-100, 0.1 % SDS, 0.85% NaCI in carbonate-bicarbonate buffer, pH 9.8). The lysate was clarified by centrifugation, stored at -80°C in aliquots, and used at a I :2000 dilution to coat plates. Other assay steps were identical to those used with the mouse IgA assay described above.
Results
Young rhesus monkeys, seronegative for antibody to RSV, were treated intranasally once daily for 2 days with one of three graded doses of mouse monoclonal IgA HNK20 or PBS placebo. Monkeys were challenged the following day with RSV (day 0), then treated with HNK20 or PBS for the next 4 days. Thus, 24 h elapsed between HNK20 treatment and RSV challenge. Treatment and viral challenge doses were given in a small volume directed to the upper airways.
Nasal swabs and throat swabs collected daily after challenge showed that mean viral shedding in placebo-treated monkeys peaked on day 6 at titers of~5 10gw/mL (figure 1). In monkeys treated with the highest dose of HNK20 (2.5 mg), mean throat and nasal swab virus titers were markedly reduced, rising to < II0glO/mL. Titers in monkeys treated with 0.5 mg ofHNK20
were reduced by as much as 210gJ()/mL, while titers in monkeys treated with 0.2 mg of HNK20 were only marginally lower than those in placebo-treated controls. Comparison of mean area under the curve (AVC) for viral shedding over the 14-day sampling period by Wilcoxon rank sum test showed significant reductions in nasal and throat swab titers in the high-dose (P .004) and intermediate-dose (P~.03) groups but not the low-dose group (P > .17).
To determine whether treatment prevented lower respiratory tract infection, BAL samples were collected at four time points after challenge. The mean virus titer in placebo-treated monkeys peaked at 3.5 10glO/mL on day 7, while no virus was recovered in samples from high-dose HNK20-treated monkeys (figure 1). The mean AVC for virus titers of the high-dose group was significantly lower than that of the placebo-treated group (P = .002). Lower doses of HNK20 had lesser effects that were not statistically significant (P > .33).
Peak RSV titers in individual monkeys are shown in table I. All monkeys in the placebo group were infected, with peak throat and nasal swab virus titers of 4~6 10glO/mL and peak BAL virus titers of 3 -4 log) oImL. In the high-dose group, 2 No treatment was given on day of challenge. Each group contained 6 animals. Samples in which no virus was recovered « 1 10glO/mL) were assigned titer of 0.5 log.s/ml., of 6 monkeys had no detectable virus in samples from any of the three sampling sites. In the intermediate-and low-dose groups, virus was recovered in all samples but with mean peak titers lower than those of control monkeys. Reductions in mean peak titers were significant (P~.05, Wilcoxon rank sum) at all sampling sites in the high-dose group. Titers were also significantly reduced in throat and nasal swab samples of the intermediate-dose group and in BAL samples of the low-dose group (P :-:s; .05). Sera collected on day 21 after challenge were tested for neutralizing activity against RSV. All monkeys developed neutralizing titers of 1:10 or greater, even in the absence of detectable viral shedding (table 1). There were no significant differences in mean neutralizing titers between the placebo group and any treatment group.
The apparently prolonged duration of protection by HNK20 in rhesus monkeys prompted us to examine how long intranasally delivered HNK20 remains in respiratory tract secretions. An antigen-capture ELISA for mouse IgA was used to measure HNK20 levels in the swab and BAL samples taken from treated animals. Nasal swab samples collected during or immediately after treatment with 2.5 mg of HNK20 (days 1-5) contained HNK20, but levels varied widely, ranging from barely detectable «2 ng/mL) to >800 ng/mL. It appeared that certain monkeys had HNK20 levels consistently higher or lower than the mean concentration. Mean concentrations ranged from 129 to 288 ng/mL on days 1-5 and fell to <20 ng/mL by day 7 (figure 2). In 4 monkeys, nasal swab HNK20 concentration fell below detectable levels between days 6 and 9. A fifth monkey had detectable HNK20 through day 13, and in the sixth, Discussion Figure 2 . Mean concentration ofHNK20 in nasal swabs from monkeys treated intranasally with 2.5 or 0.5 mg of HNK20. Arrows indicate HNK20 treatment, given once daily on days -2, -1, and 1-4. Treatment was given just after swabs were collected. HNK20 was quantitated by antigen-capture ELISA that measured mouse IgA. present in samples from day 10 or 14. In 1 monkey, HNK20 could still be detected at <2 ng/mL on day 14.
As a measure of the functional capacity of HNK20 in nasal secretions, swab samples were tested in a quantitative assay in which RSV antigen was used to capture mouse IgA. HNK20 levels in nasal swab samples from days 5 and 9 were in agreement with those measured by the antigen capture assay, suggesting that HNK20 IgA in nasal secretions was probably intact and fully capable of binding RSV (table 2) . --Outbreaks of RSV infection occur yearly in humans during the winter months. Virus is spread through direct contact or by deposition on mucosal surfaces in droplets, leading to initial infection in the upper airways [16] . Almost all children are infected by the age of 2 years, and 40% of primary infections spread to the lower respiratory tract, causing bronchiolitis or pneumonia [14] . Conditions predisposing children to severe lower respiratory tract disease include bronchopulmonary dysplasia, congenital heart disease, premature birth, and a compromised immune system [2, 14] .
Studies in animals have shown that passive antibody treatment before or during RSV infection can decrease viral replication. Lower respiratory tract infection is reduced by either parenteral or intranasal treatment with antibodies to RSV [4] [5] [6] [7] [8] [9] [10] [11] 17] , while upper respiratory tract infection is reduced most effectively by intranasal treatment [12] . We demonstrated re-HNK20 could still be detected on day 14, the final sampling point. HNK20 was found at low levels in day 1-5 nasal swabs of monkeys treated with 0.5 mg of HNK20 (figure 2), with the highest concentration being 148 ng/mL. All nasal swab samples collected from monkeys in the placebo group tested negative for HNK20.
Throat swab and BAL samples from the high-dose and placebo groups were also tested for HNK20 concentration. Two of 6 throat swabs from the high-dose group collected on day 5 contained low levels ofHNK20 (2 and 8 ng/mL). No HNK20 was detected in samples from day 6 or 7 or in any placebo group samples. BAL samples from day 4 did not contain detectable HNK20, indicating that treatment was directed to the upper airways only, as intended. HNK20 did appear in day 7 BAL samples of 4 monkeys, however, at levels ranging from 11 to 85 ng/mL. In most of these animals, HNK20 was no longer * Nasal swabs and throat swabs were collected daily for 14 days following viral challenge. Bronchoalveolar lavage (BAL) samples were collected 4, 7, 10, and 14 days after viral challenge. Samples were titrated for RSV on HEp-2 cells in half-log., dilution steps.
t Reciprocal of highest serum dilution that neutralized tissue culture infectivity by 100 infectious doses of RSV. Blood was collected 21 days after viral challenge. NOTE. -, HNK20 was undetectable. * Concentration ofHNK20 in nasal swab samples was determined by ELISA that captures HNK20 with anti-mouse IgA. HNK20 could be detected (+) in day 9 sample from monkey N058 but was below limit of quantitation (~2 ng/ mL).
t Concentration of HNK20 in nasal swab samples was determined by ELISA that captures HNK20 with RSV antigen.
cently that intranasal delivery of HNK20, a mouse monoclonal IgA antibody against RSV F glycoprotein, reduces viral replication in the nasal turbinates of mice [12] .
In the study presented here, we have extended these findings in a rhesus monkey model of RSV infection. To mimic natural infection, virus was directed to the upper airways by use of a small-volume inoculum (0.25 mL/nostril) and light sedation of monkeys during challenge. Using this procedure, virus replicated to high titer in the upper airways and to moderate titer in the lower respiratory tract. Results for virus titers and duration of shedding were comparable to those seen in African green monkeys challenged intratracheally or intranasally with RSV [18] . Although we attempted to limit initial virus infection to the upper airways, aspiration of a small portion of the inoculum into the trachea could not be ruled out.
The schedule of HNK20 treatment used in this study was designed to test whether once-daily treatment with antibody in nose drops could provide effective protection against RSV infection. Antibody was administered in the same manner as the virus challenge, so it was directed to the upper respiratory tract. Nearly complete abrogation of upper and lower respiratory tract infection by HNK20 treatment was observed at the highest dose of 2.5 mg (~0.5 mg/kg), and substantial reductions in viral replication were seen at a dose of 0.5 mg. The effect of HNK20 treatment on virus titers in rhesus monkeys was greater than that seen previously in African green monkeys immunized with RSV vaccines [18] . Upper airway treatment of monkeys with HNK20 was also very effective in reducing BAL sample RSV titers, even in the presence of viral replication in the upper airways.
Clinical studies have shown that intravenous treatment of high-risk infants with purified human IgG containing anti-RSV antibody reduces the frequency of lower respiratory tract infection and hospitalization time, but prophylactic doses of 750 mg/kg were required to show significant effects [19, 20] . Animal studies, however, have shown that antibody applied topically to the lungs can be effective at much lower doses than antibody delivered parenterally [6, 10] . Our study in monkeys showed nearly complete protection with intranasal application of HNK20 at only 0.5 mg/kg, showing that topical delivery of monoclonal antibody can be highly efficient for reduction of RSV replication. The results are in agreement with those of our previous study, in which intranasal treatment of mice with HNK20 at 0.5 mg/kg provided maximal protection against RSV infection [12] . Monkeys were challenged with RSV at a dose (lOS.7 TCID so ) that is likely to exceed what might be encountered in nature, suggesting that HNK20 could be more effective against natural infection of humans.
All monkeys developed comparable levels of viral neutralizing antibody in serum, even though viral replication could not be detected in some HNK20-treated monkeys. The finding suggests that low-level replication was sufficient to stimulate immunity to RSV. Indeed, the HNK20-treated monkeys could not be infected when rechallenged 50 days after the initial infection and treatment (Traina-Dorge V, et aI., unpublished data).
Studies in humans show that substances applied to the nasal mucosa are largely cleared by mucociliary activity in as little as 20 min [21] . We found, however, that HNK20 could be detected in nasal swab specimens of rhesus monkeys for days after intranasal application. HNK20 levels in nasal swabs collected 24 h after treatment reached close to 1 j.lg/mL in some animals treated with 2.5 mg of HNK20. This prolonged nasal residence time might explain why treatment only once per day was sufficient to protect against RSV infection.
According to our results, HNK20 remained in nasal secretions at neutralizing levels for a surprising length of time, which brings into question the validity of virus titrations in the presence of neutralizing antibody. We reported previously that HNK20 at 100 ng/mL neutralizes 50% (0.3 logJO) of RSV plaques [12] . In the same study, we found that HNK20 neutralized 0.5 and 0.710g JO of virus at 500 and 1000 ng/mL, respectively (unpublished data). Thus, it is possible that residual HNK20 in nasal swab samples, which reached concentrations as high as 900 ng/mL, could cause artificially low virus titers due to in vitro neutralization, but this effect could account for no more than a small portion of the observed reductions in virus titers. After day 5, HNK20 levels fell below neutralizing levels without any apparent effect on virus titers in HNK20-treated animals. Furthermore, throat swab virus titers paralleled nasal swab titers, but little HNK20 could be measured in throat swab samples. Thus, it appears that HNK20 in samples had little effect on determination of virus titers.
Development of a vaccine to prevent disease due to RSV lower respiratory tract infection has been unsuccessful to date. An early formalin-inactivated RSV vaccine stimulated immunity in human subjects but potentiated disease in many of the recipients who were later infected with RSV [2] . Subunit and attenuated viral vaccines, which are under development by several groups, may provide safe and effective protection in the future. Even a highly effective vaccine, however, may not protect infants with poorly developed immune systems or circulating maternal antibody to RSV. Passive antibody immunization could provide immunoprophylaxis when vaccination is not possible. The study presented here suggests that daily nosedrop antibody treatment with mouse monoclonal IgA antibody could be a simple and convenient strategy for prophylactic control of RSV infection in high-risk children.
